CYNK-101

Generic Name: CYNK-101

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1

Terminated

Conditions: Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions: Biological: CYNK-101
Drug: Pembrolizumab
Drug: Trastuzumab
Drug: Recombinant Human Interleukin-2
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna

First Posted Date: 2022-01-26

Last Posted Date: 2024-12-12

Lead Sponsor: Celularity Incorporated

Target Recruit Count: 1

Registration Number: NCT05207722

Locations: 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Scripps Health, La Jolla, California, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy